



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم

# بسم الله الرحمن الرحيم



**HANAA ALY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم



# شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



**HANAA ALY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم

# جامعة عين شمس

## التوثيق الإلكتروني والميكروفيلم

### قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



### يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



**HANAA ALY**



# Screening of Oral Tamoxifen Ocular Toxicity in Breast Cancer Patients

## Thesis

Submitted to Faculty of Medicine, Ain Shams University for  
partial fulfillment of Master Degree in Ophthalmology

## Presented by

*Mai Mohamed Ahmed Ahmed*

*M.B., B.Ch*

*Faculty of Medicine, Misr University for Science and Technology  
(MUST)*

## Under Supervision of

**Prof. Dr. Abdelrahman Gaber Salman**

*Professor of Ophthalmology*

*Faculty of Medicine, Ain Shams University*

**Dr. Randa Hesham Ali Abdelgawad**

*Lecturer of Ophthalmology*

*Faculty of Medicine, Ain Shams University*

**Dr. Ahmed Said Ibrahim Abd El Motaal**

*Lecturer of Clinical Oncology*

*Faculty of Medicine, Ain Shams University*

**Dr. Ahmed Tharwat Abdelfattah**

*Lecturer of Ophthalmology*

*Misr University for Science and Technology (MUST)*

Faculty of Medicine, Ain Shams University  
Cairo- Egypt -2021

# Acknowledgments

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Abdelrahman Gaber Salman**, Professor of Ophthalmology, Faculty of Medicine, Ain Shams University, for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. Azza Mohamed Ahmed Said**, Professor of Ophthalmology, Faculty of Medicine – Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Randa Hesham Ali Abdelgawad**, Lecturer of Ophthalmology, Faculty of Medicine – Ain Shams University, for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I would like to thank **Dr. Ahmed Said Ibrahim Abd El Motaal**, Lecturer of Clinical Oncology, Faculty of Medicine – Ain Shams University, for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I'd like to express my respectful thanks and profound gratitude to **Dr. Ahmed Tharwat Abdelfattah**, Lecturer of Ophthalmology, Misr University for Science and Technology (MUST), for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I'd like to express my respectful thanks and profound gratitude to **Dr. Samah Mahmoud Fawzy**, lecturer of Ophthalmology, Faculty of Medicine – Ain Shams University, for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*Finally, would like to express my appreciation and gratitude to all my family, especially my caring and loving parents for their support till this work was completed.*

**Mai Mohamed Ahmed Ahmed**



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا  
إلا ما علمتنا إنك أنت  
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

# Contents

Title	Page No.
List of Abbreviations.....	i
List of Tables .....	iii
List of F igures.....	vi
Introduction .....	1
Aim of the Work .....	4
Review of Literature	
Breast cancer .....	5
Ocular Toxicity of Tamoxifen .....	16
Diagnosis of Tamoxifen Ocular Toxicity .....	24
Patients and Methods .....	40
Results .....	49
Discussion.....	88
Conclusion.....	93
Recommendations.....	95
Summary .....	96
References .....	99
Arabic Summary .....	---

# List of Abbreviations

Abb.	Full term
<b>ASCO</b>	American Society of Clinical Oncology
<b>BCVA</b>	Best Corrected Visual Acuity
<b>BMI</b>	Body mass index
<b>BRCA</b>	Breast Cancer gene
<b>CMT</b>	Central macular thickness
<b>DNA</b>	Deoxyribonucleic acid
<b>EBCTCG</b>	Early Breast Cancer Trialists' Collaborative Group
<b>EPIC</b>	European prospective investigation into cancer and nutrition
<b>ER</b>	Estrogen receptor
<b>ERG</b>	Electroretinography
<b>ETDRS</b>	Early Treatment Diabetic Retinopathy Study
<b>GCC</b>	Ganglion cell complex
<b>HER-2</b>	Human epidermal growth factor receptor 2
<b>HRT</b>	Hormone replacement therapy
<b>IOP</b>	Intraocular pressure
<b>ISCEV</b>	International Society for Clinical Electrophysiology of Vision
<b>MAPK-ERK</b>	Mitogen-activated protein kinases extracellular signal-regulated kinases
<b>MD</b>	Mean deviation
<b>MFERG</b>	multifocal electroretinogram
<b>MPOD</b>	Macular pigment optical density
<b>NCI</b>	Egypt National Cancer Institute
<b>PI3K/Akt</b>	Phosphoinositide-3-Kinase, protein Kinase B
<b>PERG</b>	Pattern electroretinogram
<b>PR</b>	Progesterone receptor
<b>PROS</b>	Preserved photoreceptor outer segment



<b>RNFL</b>	Retinal nerve fiber layer
<b>RPE</b>	Retinal pigment epithelium
<b>SD</b>	Standard deviation
<b>SD-OCT</b>	Spectral domain optical coherence tomography
<b>SERM</b>	Selective estrogen receptor modulator
<b>SWS</b>	Short wavelength sensitive
<b>TNM</b>	Tumor-Node-Metastasis staging
<b>VEP</b>	Visual evoked potential

# List of Tables

Table No.	Title	Page No.
1	Mean age of studied patients.....	49
2	Mean duration of tamoxifen therapy. ....	50
3	Duration of tamoxifen therapy divided into 2 groups. ....	50
4	BCVA (logMAR) and its correlation to duration of tamoxifen therapy.....	51
5	Summary of BCVA (logMAR) difference between two groups regarding duration of tamoxifen intake .....	52
6	Mean value of IOP value and its correlation to duration of tamoxifen therapy.....	52
7	Mean IOP value difference between two groups regarding duration of tamoxifen intake .....	53
8	Summary of cup disc values and its correlation to tamoxifen intake duration .....	54
9	Summary of cup disc values and disc parameters difference between two groups regarding duration of tamoxifen intake .....	54
10	RPE mottling distribution among the studied patients.....	55
11	RPE mottling affection difference between two groups regarding duration of tamoxifen .....	55
12	Descriptive values of mean average peripapillary Retinal Nerve Fiber layer (RNFL) thickness in our study.....	57
13	Summary of average peripapillary Retinal Nerve Fiber Layer (RNFL) values and their correlation to tamoxifen therapy duration .....	58
14	Descriptive data of average peripapillary Retinal Nerve fiber layer (RNFL) affection.....	59
15	Summary of difference peripapillary Retinal Nerve Fiber layer (RNFL) values between both groups regarding duration of tamoxifen intake in both groups .....	60

# List of Tables (cont..)

Table No.	Title	Page No.
16	Summary of difference peripapillary Retinal Nerve fiber layer (RNFL) affection between both groups regarding duration of tamoxifen intake .....	61
17	Descriptive values of mean macular thickness in our study in different quadrants.....	64
18	Descriptive data of total macular thickness affection in our study.....	65
19	Summary of mean macular thickness in different quadrants and its correlation to tamoxifen intake duration .....	66
20	Summary of mean macular thickness comparing both groups.....	67
21	Summary of total macular thickness affection between both groups regarding duration of tamoxifen intake .....	68
22	Summary of average Ganglion cell complex (GCC) thickness values .....	71
23	Descriptive data of Average Ganglion cell complex (GCC) affection.....	72
24	Summary of average Ganglion cell complex (GCC) and its correlation to duration of tamoxifen.....	73
25	Summary of mean of average Ganglion Cell Complex (GCC) complex thickness values difference in both groups regarding duration of tamoxifen intake .....	74
26	Summary of average Ganglion Cell Complex (GCC) complex affection difference between both groups.....	75
27	IS/OS layer thickness disruption among the studied patients .....	76
28	ERG affection among the studied patients.....	78
29	Color vision affection among the studied patients .....	81

## List of Tables (cont..)

Table No.	Title	Page No.
<b>30</b>	Summary of color vision affection to duration of tamoxifen therapy .....	81
<b>31</b>	Summary of total macular thickness values to color vision affection .....	83
<b>32</b>	Summary of parameters in our study and their correlation to duration of tamoxifen .....	86
<b>33</b>	Descriptive data of parameters used in our study and their correlation to duration of tamoxifen therapy .....	87

# List of Figures

Fig. No.	Title	Page No.
1	Distribution of estimated female breast cancer new cases, deaths, and 5-year prevalence by world region, 2012 .....	6
2	Breast cancer incidence rates/100,000 person-years by age group and year of diagnosis, 1999–2008 .....	7
3	Mechanisms of Action and Resistance in Estrogen Receptor (ER)–Targeted Therapy .....	10
4	Fundus photography of both eyes of one patient showing crystalline deposits in perifoveal area .....	19
5	A and B, Slit-lamp external photograph of the right eye shows subepithelial crystallin-like substance deposition in the cornea .....	22
6	Slit-lamp examination (A) and cobalt blue filter after fluorescein instillation (B) of the patient’s right eye depicting whorl-like, subepithelial deposits sparing the periphery and central cornea .....	22
7	Ishihara color vision test plates .....	25
8	Ishihara color vision test plates .....	26
9	SD-OCT of the right eye. The black arrow showed the hyperreflective substances between the ganglion cell layer and inner plexiform layer correspond with the refractile deposits .....	29
10	SD-OCT of the left eye. A defect in the outer retinal layer with sharp edges can be seen .....	29
11	SD-OCT of the right eye. A disruption of the photoreceptor layer can be seen. ....	30
12	SD-OCT showed bilateral disruption of the ellipsoid zone and interdigitation zone .....	30
13	The biphasic waveform of the ERG of a normal patient .....	31

# List of Figures (cont..)

Fig. No.	Title	Page No.
14	Representative fullfield ERG waveforms from a tamoxifen subject according to The International Society for Clinical Electrophysiology of Vision (ISCEV) standard protocol .....	33
15	A typical standard PERG.....	35
16	(A) MFERG trace array derived from 103 mfERG responses of the first-order kernel. (B) Three-dimensional plot of multifocal ERG response density.....	37
17	Visual evoked potential in a case of tamoxifen toxicity. ....	39
18	Fransworth panel D-15 device used in our study. ....	43
19	Fransworth panel D-15 device used in our study. ....	43
20	Retnia scan RS 3000 advance nidek OCT device used in our study.....	44
21	RETI port/san 21 Electrophysiology device used in our study.....	45
22	OCT optic nerve scan of one of our patients. ....	46
23	OCT-macula map of one of our patients. ....	46
24	OCT-of ganglion cell complex (GCC) of one of our patients.....	47
25	Pie diagram showing groups of tamoxifen therapy intake.....	51
26	OCT optic nerve scan of one of our patients shows within normal average RNFL thickness in both eyes.....	62
27	OCT optic nerve scan of one of our patients shows thinning of average RNFL thickness in superior half of right eye. ....	62
28	OCT optic nerve scan of one of our patients shows below normal thinning of average RNFL thickness in nasal quadrant of rt eye and borderline thinning of average RNFL thickness in nasal quadrant of left eye. ....	63



# List of Figures (cont..)

Fig. No.	Title	Page No.
29	OCT- macula map of one of our patients shows within normal average total macular thickness, GCC shows within average normal thickness in both eyes.....	69
30	OCT macula map of one of our patients shows borderline thinning of the average total macular thickness in nasal and lower quadrants in outer ring in left eye.....	69
31	OCT-macula map of one of our patients shows borderline thinning of the central macular thickness of both eyes and borderline thinning in superior quadrant of left eye and temporal quadrant of right eye in the 3 mm zone.....	70
32	Pie diagram showing IS/OS layer thickness among the studied group (N=50).....	76
33	OCT-macula radial of one of our patients shows interruption in IS/OS layer thickness in both eyes. ....	77
34	OCT-macula radial of one of our patients shows interruption in IS/OS layer thickness in both eyes. ....	77
35	PERG of one of our patients shows delayed N95 wave in Right eye. ....	79
36	MFERG of one of our patients showed reduced P1 amplitude in ring 1.....	80
37	Pie diagram showing color vision defects distribution among the studied group (N=50).....	82
38	Fransworth D-15 Hue test of patient in our study with normal color vision. ....	84
39	Fransworth D-15 Hue test of patient in our study with tritanomaly. ....	84
40	Fransworth D-15 Hue test of patient in our study with protanomaly. ....	85
41	Fransworth D-15 Hue test of patient in our study with deutanomaly. ....	85